The Scripps Research Institute, the La Jolla, CA-based nonprofit research center, said today it will establish, along with the International AIDS Vaccine Initiative, the world’s first research center devoted to studying neutralizing antibodies against HIV. The International AIDS Vaccine Initiative will invest $30 million over five years in the center at Scripps, to house teams of scientists from multiple disciplines who will study how to generate broadly neutralizing antibodies against the HIV virus. Scripps president Richard Lerner called it “the toughest challenge facing AIDS vaccine researchers today,” in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
